Coronary benefits of calcium antagonist therapy for patients with hypertension

Current Opinion in Cardiology

Volumn 16, Issue 6, 2001, Pages 349-355

  Motro, Michael ^a   Shemesh, Joseph ^a   Grossman, Ehud ^a,b  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; BENZOTHIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; COLLAGEN; DIHYDROPYRIDINE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ELASTIN; PHENYLALKYLAMINE;

ANGINA PECTORIS; ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; CARDIOVASCULAR FUNCTION; CORONARY ARTERY BLOOD FLOW; DIABETES MELLITUS; DRUG EFFECT; HUMAN; HYPERTENSION; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; VASCULAR RESISTANCE;

ANGINA PECTORIS; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; CORONARY ARTERIOSCLEROSIS; CORONARY VESSELS; DIABETES MELLITUS; ENDOTHELIUM, VASCULAR; HUMANS; HYPERTENSION; HYPOTENSION; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 0035211609     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001573-200111000-00006     Document Type: Review

References (96)

1. Shanghai trial of nifedipine in the elderly (STONE)
2. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators
3. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group
4. Randomised trial of old and new antihypertensive drugs in elderly patients: Cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study
5. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT)
6. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: The Nordic Diltiazem (NOR-DIL) study
7. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine
8. Regulatory functions of the vascular endothelium
9. Intact and altered endothelium in regulation of vasomotion
10. Atherosclerosis or lipoprotein-induced endothelial dysfunction. Potential mechanisms underlying reduction in EDRF/nitric oxide activity
11. The L-arginine-nitric oxide pathway
12. Coronary risk factors, endothelial function, and atherosclerosis: A review
13. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension
14. Indirect evidence for release of endothelium-derived relaxing factor in human forearm circulation in vivo. Blunted response in essential hypertension
15. Selective attenuation of endothelium-mediated vasodilation in atherosclerotic human coronary arteries
16. Activation of endothelial L-arginine pathway in resistance arteries. Effect of age and hypertension
17. Aging and endothelial function in normotensive subjects and patients with essential hypertension
18. Impaired vasodilation of forearm resistance vessels in hypercholesterolemic humans
19. Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus
20. Long-term cigarette smoking impairs endothelium-dependent coronary arterial vasodilator function
21. Endothelium-dependent contractions to acetylcholine in the aorta of the spontaneously hypertensive rat
22. Endothelium-dependent vascular responses in normotensive and hypertensive Dahl rats
23. Impaired endothelium-dependent relaxations in hypertensive resistance arteries involve cyclooxygenase pathway
24. Endothelium-dependent and endothelium-independent vasodilation in resistance arteries from hypertensive rats
25. Epicardial coronary artery responses to acetylcholine are impaired in hypertensive patients
26. Antihypertensive treatment normalizes decreased endothelium-dependent relaxations in rats with salt-induced hypertension
27. Role of endothelium-derived nitric oxide in the abnormal endothelium-dependent vascular relaxation of patients with essential hypertension
28. Effect of antihypertensive treatment on endothelium-dependent vascular relaxation in patients with essential hypertension
29. Antihypertensive therapy augments endothelium-dependent relaxations in coronary arteries of spontaneously hypertensive rats
30. Dual mode of action of dihydropyridine calcium antagonists: A role for nitric oxide
31. Coronary and cardiac sensitivity to the vasoselective benzothiazepine-like calcium antagonist, clentiazem, in experimental heart failure
32. Calcium-channel blockers preserve coronary endothelial reactivity after ischemia-reperfusion
33. Nifedipine-induced coronary vasodilation in ischemic hearts is attributable to bradykinin and NO dependent mechanisms in dogs
34. Amlodipine releases nitric oxide from canine coronary microvessels: An unexpected mechanism of action of a calcium channel-blocking agent
35. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide
36. Evidence for nitric oxide generation in the cardiomyocytes: Its augmentation by hypoxia
37. Evidence for the presence of L-arginine-nitric oxide pathway in human red blood cells: Relevance in the effects of red blood cells on platelet function
38. Current status of platelet NO synthases
39. Expression of nitric oxide synthase in human peripheral blood mononuclear cells and neutrophils
40. Salicylate or aspirin inhibits the induction of the inducible nitric oxide synthase in rat cardiac fibroblasts
41. Normalization of abnormal coronary vasomotion by calcium antagonists in patients with hypertension
42. Antiatherogenic properties of the calcium antagonists
43. Antiatherogenic properties of the calcium antagonists
44. Calcium antagonists as antiatherosclerotic agents
45. Atherogenesis, calcium and calcium antagonists
46. Antihypertensive and arterial anticalcinotic effects of calcium antagonists
47. Experimental basis of the long term therapy of arterial hypertension with calcium antagonists
48. Limits of lipid-lowering therapy: The benefits ofam-Iodipine and anti-atherosclerotic agent
49. The antiatherogenic effects of amlodipine: Promise of preclinical data
50. Retardation of angiographic progression of coronary artery disease by nifedipine. Results of the International Nifedipine Trial on Antiatherosclerotic Therapy (INTACT)
51. Comparison of nifedipine, propranolol and isosorbide dinitrate on angiographic progression and regression of coronary arterial narrowing in angina pectoris
52. A controlled clinical trial to assess the effect of a calcium channel blocker on the progression of coronary atherosclerosis
53. Atheroprotection with amlodipine: Cells to lesions and the PREVENT trial. Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial
54. Rationale, design, and baseline characteristics of the Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial (PREVENT)
55. Effect of calcium channel blocker amlodipine on the intimal-medial thickness of carotid arterial wall in type 2 diabetes
56. Restenosis and clinical outcome in patients treated with amlodipine after angioplasty: Results from the Coronary Angioplasty Amlodipine REStenosis Study (CAPARES)
57. Effect of HMG-CoA reductase inhibitors on coronary artery disease as assessed by electron-beam computed tomography
58. The calcium channel blocker nifedipine slows down progression of coronary calcification in hypertensive patients as compared to diuretics
59. Excessive mural calcium overload - A predominant causal factor in the development of stenosing coronary plaques in humans
60. Coronary arterial calcification: A review
61. Coronary artery calcification: Pathophysiology, epidemiology, imaging methods and clinical implications. A statement for health professionals from the American Heart Association
62. Calcification of coronary arteries: Detection and quantification with double-helix CT
63. Measurement of coronary artery calcium with dual-slice helical CT compared with coronary angiography: Evaluation of CT scoring, methods, interobserver variations, and reproducibility
64. Noninvasive definition of anatomic coronary artery disease by ultrafast computed tomographic scanning: A quantitative pathologic comparison study
65. Coronary artery calcium area by electron-beam computed tomography and coronary atherosclerotic plaque area. A histopathologic correlative study
66. Absence of coronary calcification on double-helical CT scans: Predictor of angiographically normal coronary arteries in elderly women?
67. Noninvasive prediction of coronary atherosclerosis by quantification of coronary artery calcification using electron beam computed tomography. Comparison with electrocardiographic and thallium exercise stress test results
68. Evidence for a synergistic effect of calcium channel blockers with lipid-lowering therapy in retarding progression of coronary atherosclerosis in symptomatic patients with normal to moderately raised cholesterol levels
69. Enhanced vasodilatation in essential hypertension by calcium channel blockade with verapamil
70. The effects of the calcium antagonist nifedipine on pressor and aldosterone responses to angiotensin II in normal man
71. Natriuretic effect of calcium- channel blockers in hypertensives
72. Long acting nifedipine in moderate and severe hypertensives with serious concomitant diseases
73. Cardiovascular effects of verapamil in patients with essential hypertension
74. Systemic and regional hemodynamic and humoral effects of nitrendipine in essential hypertension
75. Cardiovascular effects of isradipine in essential hypertension
76. Antihypertensive care with calcium antagonists
77. A comparison of the efficacy and safety of a beta-blocker, a calcium channel blocker, and a converting enzyme inhibitor in hypertensive blacks
78. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension
79. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM
80. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP) randomised trial
81. Comparison of antihypertensive treatments in preventing cardiovascular events in elderly diabetic patients: Results from the Swedish Trial in Old Patients with Hypertension-2
82. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension
83. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators
84. High blood pressure and diabetes mellitus: Are all antihypertensive drugs created equal?
85. First line drugs in chronic stable effort angina - The case for newer, longer-acting calcium channel blocking agents
86. 24 Hours anti-anginal and anti-ischaemic effects with once daily felodipine. A double-blind comparison with nifedipine, twice daily, and placebo in patients with stable exercise induced angina pectoris
87. Effect of calcium antagonists in variant or Prinzmetal angina
88. Update of effects of calcium antagonists in myocardial infarction or angina in light of the second Danish Verapamil Infarction Trial (DAVIT II) and other recent studies
89. Nifedipine: Dose related increase in mortality in patients with coronary heart disease
90. Effect of calcium antagonists on plasma norepinephrine levels, heart rate, and blood pressure
91. Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: A meta-analysis of randomised controlled trials
92. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: Results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration
93. Effect of verapamil on mortality and major events acute myocardial infarction (The Danish Verapamil Infarction Trial-II-DAVIT II)
94. The effect of diltiazem on mortality and reinfarction after myocardial infarction
95. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: The antihypertensive lipid-lowering treatment to prevent heart attack trial (ALLHAT)